33 Clinical, Medical & Diagnostic Products Medical Device Components that Inhibit Bacterial Growth
Vyon® porous plastics from Porvair Sciences are the perfect material for filtration applications in the healthcare and medical device market The tortuous path of Vyon® porous plastics make these materials particularly effective at bacterial filtration and preventing microbial ingress. Manufactured to a variety of pore sizes and thickness, Vyon® porous plastic materials can also be used to filter out a wide variety of different contaminating particles.
Employing a standard procedure, based upon ASTM F2101, Porvair Sciences can manufacture for OEM partners - Vyon® porous plastic filters for incorporation into a medical device that offer greater than 99% Bacterial Filtration Efficiency (BFE).
Porvair Sciences is a leading OEM supplier of pipette tip filters that are highly effective at inhibiting bacterial growth as well as being fully compliant with FDA, USP Class VI and European Pharmacopoeia statutory regulations. To discuss development of a porous plastic component for your medical device that offers high bacterial filtration efficiency please contact Porvair Sciences Ltd or visit Stand 8AF08 at Compamed 2022.
More information online:
ilmt.co/PL/Z2Ev 58798pr@reply-direct.com
Fully Automated Platform for Molecular Diagnostic Laboratories
A fully integrated solution, the new and completely automated RIDA®UNITY system combines sample extraction, PCR setup, real-time PCR and result evaluation in a common workflow. Leading biotechnology company R-Biopharm AG has announced that it has received the CE mark and will begin selling the RIDA®UNITY system for molecular detection of infectious diseases throughout Europe.
“With the RIDA®UNITY system, R-Biopharm is purposefully taking the path from a provider of individual solutions to a system provider in the field of molecular diagnostics,” stated Christian Dreher, CEO of R-Biopharm. “We are very happy to make this system solution available to all molecular biology laboratories throughout Europe.”
The RIDA®UNITY system combines the various steps in the analysis of patient samples into an integrated workflow - nucleic acid extraction, PCR setup, subsequent real-time PCR and the evaluation of the results run fully automatically without user intervention. The ready-to-use RIDA®UNITY reagents significantly reduce the preparation times in the laboratory. The RIDA®UNITY Universal Extraction Kit allows the universal extraction of nucleic acids from both gastrointestinal and respiratory patient samples in a common workflow and was specifically developed and optimised by R-Biopharm. Up to six
different RIDA®UNITY PCR assays can now be individually combined and processed.
The software especially developed for the RIDA®UNITY system supports the user with its simple and intuitive operation - from loading the required consumables and positioning the PCR reagents on the deck up to evaluating the final results. The RIDA®UNITY system supports molecular diagnostic laboratories with its flexibility in dealing with quickly changing requirements and thus noticeably facilitates everyday work in the laboratory.
“Today we can finally present the result of an incredible effort of diverse teams and many colleagues both from internal as well as external sources,” said Dr Lena Kastl, Vice President Clinical Diagnostics at R-Biopharm. “R-Biopharm’s many years of product development and manufacturing expertise and the productive cooperation with various partners made the roll-out of this new molecular diagnostic platform possible. Thanks to its efficient, intuitive and universal application options, RIDA®UNITY will significantly support and improve workflow and capacities in the laboratories in the future.”
The RIDA®UNITY System, the RIDA®UNITY Universal Extraction Kit and the RIDA®UNITY Bacterial Stool Panel are now available for sale throughout Europe. More information online:
ilmt.co/PL/vByM
58293pr@reply-direct.com Rapid Diagnostic System Successfully Deployed at the 2022 Commonwealth Games
ProtonDx, a health technology company developing robust, point-of-need diagnostic solutions, announced that Dragonfly™, its portable, rapid diagnostic system, formed a key part of the diagnostic testing portfolio used by Team Scotland during the 2022 Commonwealth Games in Birmingham, UK. Team Scotland’s request to use the system was a direct result of the highly positive experience, earlier this year, of Dragonfly’s use by Team GB at the 2022 Olympic Winter Games held in Beijing, China.
Using proprietary ultra-fast nucleic acid extraction, and isothermal colourimetric detection, the system achieves PCR-equivalent sensitivity and specificity in less than 30 minutes from sample to result. The 5-in-1 Respiratory Test Panel detects severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Influenza A Virus (IAV), Influenza B Virus (IBV), Respiratory Syncytial Virus (RSV) and Human Rhinovirus (HRV) in a single test.
Dr Niall Elliott, Chief Medical Officer, Team Scotland, said: “It has taken years of intense training and focused preparation for Scotland’s best athletes to compete in the 2022 Commonwealth Games. The recent COVID-19 pandemic has made us more attuned to how vital it is to be able to quickly assess athletes’ health using a system that is highly portable and can test for multiple viruses in parallel. With the successful use of Dragonfly in Beijing, we approached ProtonDx about using this diagnostic tool during the Commonwealth Games. We appreciate our strong relationships and coordinated efforts with Team GB and ProtonDx, and value the innovative Dragonfly technology.”
Bob Enck, Chairman and President of ProtonDx, stated: “Dragonfly’s successful deployment in elite sports is a testament to the reliability, ease-of-use, and portability of the system that we saw during its use by Team GB at the Olympic Winter Games. Dragonfly is a potential game-changer in the diagnostics industry - providing quick, cost-effective, and confident results, irrespective of location. With its demonstrated value at major international sporting events, the interest in Dragonfly throughout the sporting world and other key industries is rapidly expanding across Europe.”
In June 2022, ProtonDx, announced that it had received a CE-IVD mark for its innovative Dragonfly multi-pathogen detection diagnostic system. The robust, accurate system is poised to help revolutionise rapid infectious disease diagnosis and tracking worldwide.
More information online:
ilmt.co/PL/30PB and
ilmt.co/PL/2Wam 58867pr@reply-direct.com
Rapid Detection of Gram Negative Bacteria
Gram negative bacteria can cause a number of disease conditions including urinary tract infections, food-borne infections, typhoid fever and sepsis. Many of these bacteria can be detected by culture. However this method is labour intensive and slow. Rapid diagnosis is crucial for correctly treating these infections quickly.
ViroStat has just released a pair of Monoclonal Antibodies that detect the LPS common to many of these bacteria including E. coli, Salmonellae and Shigella among others. These antibodies are useful tools for rapid, non-culture based immunoassays including ELISA and lateral flow to directly detect these bacteria.
Go to the ViroStat website to download the data sheet for these new antibodies. More information online:
ilmt.co/PL/Z2LX
58962pr@reply-direct.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72
